Smarter drug decisions,
powered by AI
Compete, accelerate, and find the best drug for your portfolio
The Vibe Bio impact
8x
Faster asset diligence
75%
SME workloads reduction
3
Portfolio companies funded
Why Vibe?
The future of drug development uses AI
Achieve greater agility, fresh perspectives, and sharper precision — even when expert resources are limited.
AI-powered insights, human-validated results
Perform due diligence, scan indications, dive into drug candidates, and identify high-potential programs.
Investing for cures and impact
We fund founders committed to finding cures for rare and overlooked diseases.
Biopharma business development meets AI: Accelerating due diligence to find the right assets
Watch this webinar with Alok Tayi, PhD, Founder and CEO of Vibe Bio, to learn how AI is accelerating business development and helping executive teams move faster by conducting more thorough due diligence with the same resources.
Join us to discover new cures!
Contact us to learn how to streamline your due diligence drug decisions with AI or about our venture fund.
The Vibe blog
Navigating pharma strategy and portfolio prioritization: A Q&A
With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate…
Lessons from a pioneer in pharmaceutical decision-making
Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons learned from developing portfolio management and…
Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science…
Improving biopharma BD with AI-powered due diligence
In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with…
Navigating pharma strategy and portfolio prioritization: A Q&A
With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate…
Lessons from a pioneer in pharmaceutical decision-making
Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons learned from developing portfolio management and…
Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science…
Improving biopharma BD with AI-powered due diligence
In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with…